Stockscreener 앱 받기
0.695
2.79%
-0.025
전일 마감가:
$0.72
열려 있는:
$0.71
하루 거래량:
21,427
Relative Volume:
0.20
시가총액:
$7.45M
수익:
$34.07M
순이익/손실:
$-20.13M
주가수익비율:
-0.0538
EPS:
-12.92
순현금흐름:
$-24.90M
1주 성능:
-16.58%
1개월 성능:
-5.42%
6개월 성능:
-28.43%
1년 성능:
-59.31%
1일 변동 폭
$0.689
$0.7201
1주일 범위
$0.68
$0.8142
52주 변동 폭
$0.6513
$2.22
Biofrontera Inc Stock (BFRI) Company Profile
명칭
Biofrontera Inc
전화
781-245-1325
주소
120 PRESIDENTIAL WAY,, WOBURN
BFRI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.6999 | 7.45M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
157.94 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.62 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.57 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire
Major Skin Cancer Prevention Campaign Launches as 58M Americans Face Actinic Keratosis Risk - Stock Titan
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - ADVFN
Press Release Distribution & PR Platform - ACCESS Newswire
Biofrontera Inc. (NASDAQ:BFRI) Sees Large Decrease in Short Interest - Defense World
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Revista ADVFN
Biofrontera Inc. Reports Record Sales and Strategic Advances - MSN
Virtu Financial LLC Invests $48,000 in Biofrontera Inc. (NASDAQ:BFRI) - The AM Reporter
Benchmark maintains Buy rating on Biofrontera stock, target at $7 By Investing.com - Investing.com Australia
Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Call Transcript - MSN
Benchmark maintains Buy rating on Biofrontera stock, target at $7 - Investing.com India
Biofrontera outlines 2025 growth strategies with new FDA approvals and clinical progress - MSN
Biofrontera Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada
Biofrontera Inc. Q4 2024 Earnings: A Deep Dive into the Numbers - AInvest
Biofrontera Inc. Reports Record Revenue Growth in 2024 - TipRanks
Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year - TipRanks
Earnings call transcript: Biofrontera Q4 2024 sees revenue growth and strategic shifts - Investing.com India
Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewswire Inc.
Earnings Scheduled For March 21, 2025 - Benzinga
Biofrontera Inc. (BFRI) reports earnings - Quartz
Biofrontera Inc. SEC 10-K Report - TradingView
Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses - Marketscreener.com
Biofrontera completes patient enrollment in Phase 3 study of Ameluz - TipRanks
Biofrontera Inc. Announces Completion of Patient Enrollment - GlobeNewswire
Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial - StockTitan
3 Reasons to Avoid KIND and 1 Stock to Buy Instead - The Globe and Mail
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - GlobeNewswire
Biofrontera (BFRI) to Release Earnings on Friday - Defense World
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire
BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan
Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World
Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance
Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World
Constellation Brands: A Fallen Star or a Hidden Value Play? - The Globe and Mail
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Biofrontera (NASDAQ:BFRI) vs. Sage Therapeutics (NASDAQ:SAGE) Critical Contrast - Defense World
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts - ACCESS Newswire
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals - ACCESS Newswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire
Biofrontera Inc (BFRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.35%
자본화:
|
볼륨(24시간):